Published in Law and Health Weekly, March 18th, 2006
According to a report from the University of Utah, "The benefit of adjuvant radiation therapy (RT) in stage I endometrial adenocarcinoma remains controversial despite several phase 3 trials. [Our objective was] to evaluate the frequency and effect of adjuvant RT on overall and relative survival within a large US population database."
C.M. Lee and colleagues conducted "a retrospective analysis that used data from the Surveillance, Epidemiology, and End Results program of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.